A side-by-side laboratory comparison of RT3 (LY3437943) and Tirz — receptor profile, mechanism, class, analytical release specification and research context, for UK researchers.
Triple agonist peptide targeting GLP-1, GIP and glucagon receptors — of interest in metabolic, body-composition and energy-balance research.
Shop RT3 →
Dual agonist peptide targeting GLP-1 and GIP receptors — a well-characterised reference compound in incretin research.
Shop Tirz →| Feature | RT3 | Tirz |
|---|---|---|
| Receptor profile | GLP-1 · GIP · Glucagon (triple) | GLP-1 · GIP (dual) |
| Compound class | Triple agonist peptide | Dual agonist peptide |
| Primary research interest | Triple-hormone synergism, energy expenditure, body composition | Dual-incretin biology, glycaemic and metabolic research |
| Analytical release | ≥99% HPLC-UV, mass spec identity, endotoxin | ≥99% HPLC-UV, mass spec identity, endotoxin |
| Form | Lyophilised powder | Lyophilised powder |
| Storage | 2–8°C dark; ~30 days reconstituted | 2–8°C dark; ~30 days reconstituted |
| Research maturity | Emerging triple-incretin reference | Well-characterised dual-incretin reference |
RT3 and Tirz are frequently referenced side by side because they represent adjacent generations of incretin research chemistry. Tirz established the dual GLP-1 / GIP receptor model in the laboratory literature. RT3 extends that model with a third receptor arm — glucagon — that alters the profile of energy expenditure and hepatic activity captured in research models.
Laboratory groups building comparative datasets typically procure both compounds as lyophilised powders at matched release specifications so that receptor-level contributions can be isolated. Our companion guide RT3 vs Sema completes the triangle by comparing the triple agonist against the single GLP-1 reference.
All observations here are laboratory research context. BuyRetaUK does not make clinical, therapeutic or off-label claims.
RT3 is a triple receptor agonist (GLP-1 / GIP / glucagon). Tirz is a dual receptor agonist (GLP-1 / GIP). The glucagon arm is the distinguishing feature of the triple class.
Yes. Both are engineered as long-acting peptides suitable for weekly-dosing research protocols in the studies that reference them.
Tirz is the more established dual-incretin reference; RT3 is the more recently characterised triple-incretin candidate. Many laboratories reference both together.
Yes — every batch of both compounds ships with a batch-specific Certificate of Analysis reporting HPLC purity, mass-spec identity and endotoxin data.
No. BuyRetaUK supplies both strictly for in-vitro laboratory research. Neither is approved by BuyRetaUK for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Baseline understanding of the triple agonist.
Triple vs dual receptor profile.
Triple vs single GLP-1 profile.
Verify identity and purity of any compound.
All GLP-1 / GIP / glucagon research peptides.
A laboratory overview of RT3 (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Product ComparisonsHow RT3 and Sema differ in receptor activity, compound class and laboratory research framing.
5 min read →Purity & Laboratory TestingThe quality standards BuyRetaUK applies to every batch — sourcing, analytical testing, storage and traceability.
5 min read →RT3Background on RT3 in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Triple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →The UK commercial hub for research-grade RT3 — lab data, COAs and dispatch.
Browse collection →CollectionThe full RT3 range with research context and lab data.
Browse collection →CollectionEvery GLP-1 / GIP / glucagon research peptide in one place.
Browse collection →Every batch of RT3, Tirz ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
RT3 is the more recently characterised compound in the academic literature, while Tirz is the more established reference.
Read: RT3 vs Tirz →Yes — both act on the GLP-1 receptor, but RT3 also acts on GIP and glucagon receptors.
Read: RT3 vs Sema →No. RT3 is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is RT3? →In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is RT3? →How RT3 and Sema differ in receptor activity, compound class and laboratory research framing.
5 min read — Read guide →